Logo image of IPSC

CENTURY THERAPEUTICS INC (IPSC) Stock Price, Quote, News and Overview

NASDAQ:IPSC - Nasdaq - US15673T1007 - Common Stock - Currency: USD

0.5819  0 (-0.77%)

After market: 0.5819 0 (0%)

IPSC Quote, Performance and Key Statistics

CENTURY THERAPEUTICS INC

NASDAQ:IPSC (6/20/2025, 8:00:02 PM)

After market: 0.5819 0 (0%)

0.5819

0 (-0.77%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.29
52 Week Low0.34
Market Cap50.14M
Shares86.16M
Float63.82M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-17 2021-06-17


IPSC short term performance overview.The bars show the price performance of IPSC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

IPSC long term performance overview.The bars show the price performance of IPSC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IPSC is 0.5819 USD. In the past month the price increased by 0.4%. In the past year, price decreased by -79.65%.

CENTURY THERAPEUTICS INC / IPSC Daily stock chart

IPSC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.04 327.31B
AMGN AMGEN INC 13.94 155.58B
GILD GILEAD SCIENCES INC 14.02 134.97B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.22B
REGN REGENERON PHARMACEUTICALS 11.5 55.03B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.38B
ARGX ARGENX SE - ADR 94.29 33.10B
ONC BEONE MEDICINES LTD-ADR 6.32 26.73B
BNTX BIONTECH SE-ADR N/A 25.61B
NTRA NATERA INC N/A 23.47B
INSM INSMED INC N/A 18.70B
BIIB BIOGEN INC 8.03 18.62B

About IPSC

Company Profile

IPSC logo image Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Company Info

CENTURY THERAPEUTICS INC

25 N 38Th Street, 11Th Floor

PHILADELPHIA PENNSYLVANIA US

CEO: Osvaldo Flores

Employees: 159

IPSC Company Website

IPSC Investor Relations

Phone: 12159814000

CENTURY THERAPEUTICS INC / IPSC FAQ

What is the stock price of CENTURY THERAPEUTICS INC today?

The current stock price of IPSC is 0.5819 USD. The price decreased by -0.77% in the last trading session.


What is the ticker symbol for CENTURY THERAPEUTICS INC stock?

The exchange symbol of CENTURY THERAPEUTICS INC is IPSC and it is listed on the Nasdaq exchange.


On which exchange is IPSC stock listed?

IPSC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CENTURY THERAPEUTICS INC stock?

12 analysts have analysed IPSC and the average price target is 4.49 USD. This implies a price increase of 671.27% is expected in the next year compared to the current price of 0.5819. Check the CENTURY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CENTURY THERAPEUTICS INC worth?

CENTURY THERAPEUTICS INC (IPSC) has a market capitalization of 50.14M USD. This makes IPSC a Micro Cap stock.


How many employees does CENTURY THERAPEUTICS INC have?

CENTURY THERAPEUTICS INC (IPSC) currently has 159 employees.


What are the support and resistance levels for CENTURY THERAPEUTICS INC (IPSC) stock?

CENTURY THERAPEUTICS INC (IPSC) has a support level at 0.58 and a resistance level at 0.59. Check the full technical report for a detailed analysis of IPSC support and resistance levels.


Is CENTURY THERAPEUTICS INC (IPSC) expected to grow?

The Revenue of CENTURY THERAPEUTICS INC (IPSC) is expected to grow by 2148.1% in the next year. Check the estimates tab for more information on the IPSC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CENTURY THERAPEUTICS INC (IPSC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CENTURY THERAPEUTICS INC (IPSC) stock pay dividends?

IPSC does not pay a dividend.


What is the Price/Earnings (PE) ratio of CENTURY THERAPEUTICS INC (IPSC)?

CENTURY THERAPEUTICS INC (IPSC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).


What is the Short Interest ratio of CENTURY THERAPEUTICS INC (IPSC) stock?

The outstanding short interest for CENTURY THERAPEUTICS INC (IPSC) is 3.77% of its float. Check the ownership tab for more information on the IPSC short interest.


IPSC Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to IPSC. When comparing the yearly performance of all stocks, IPSC is a bad performer in the overall market: 92.87% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IPSC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IPSC. No worries on liquidiy or solvency for IPSC as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IPSC Financial Highlights

Over the last trailing twelve months IPSC reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 86.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.89%
ROE -9.04%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%297.78%
Sales Q2Q%12667.72%
EPS 1Y (TTM)86.88%
Revenue 1Y (TTM)8268.46%

IPSC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to IPSC. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 77.6% and a revenue growth 2148.1% for IPSC


Ownership
Inst Owners50.06%
Ins Owners1.39%
Short Float %3.77%
Short Ratio3.04
Analysts
Analysts83.33
Price Target4.49 (671.61%)
EPS Next Y77.6%
Revenue Next Year2148.1%